This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Coats disease (exudative retinal vasculopathy)Coats Disease (Exudative Retinal Vascular Anomaly)

Contents and key points
ItemDetails
A. Classification codesICD-10: H35.0 | Special Copayment Reduction: V260 (5 years)
B. SynonymsCoats retinopathy, exudative retinitis
C. Adult onsetLikelihood of first onset in adulthood: low — mostly presents in children~adolescents (ages 5~10); an adult form (adult Coats) exists separately but is rare and progresses slowly
1. HistoryGeorge Coats (1908) first described exudative retinitis; Leber (1916) described retinal telangiectasia; Reese (1956) unified them as a single disease
2. CausesIdiopathic malformation (telangiectasia) of retinal capillaries and arterioles → plasma·lipid exudation → submacular lipid deposition·exudative retinal detachment; non-hereditary, sporadic
3. GeneticsMostly non-hereditary and sporadic; some associations with NDP (Norrie disease protein) variants; Coats-like changes associated with muscular dystrophy (FSHD); somatic mutation hypothesis
4. EpidemiologyRare; estimated at about 0.09 per 100,000 population; male predominance about 3:1; unilateral in about 90%; peak onset at ages 5~10; a major cause of exudative retinal detachment under age 10
5. PathophysiologyRetinal vascular endothelial cell dysfunction → breakdown of the blood-retinal barrier → subretinal exudation of plasma proteins·lipids → macular lipid deposition·exudative retinal detachment; involvement of elevated VEGF
6. SymptomsAsymptomatic early; first noticed through decreased vision, strabismus (esotropia most common), or leukocoria; with progression, pain·elevated intraocular pressure
7. SignsFundus: retinal vessel dilation·tortuosity (light-bulb aneurysm, IRMA), yellow-white exudates, retinal detachment; fluorescein angiography: capillary leakage·nonperfusion
8. ScreeningRed reflex testing in neonates~children (detection of leukocoria); strabismus screening; regular retinal examination in patients with muscular dystrophy
9. DiagnosisFluorescein angiography (FFA) + B-scan ultrasound + fundus photography; differentiation from retinoblastoma is clinically most important; MRI/CT as adjuncts
10. TreatmentLaser photocoagulation (first-line treatment), cryotherapy, intravitreal anti-VEGF injection (adjunct), steroids; vitrectomy with progression; Stage 5: consider enucleation
11. PrognosisVision can be preserved with early diagnosis·treatment; progressive forms carry a risk of blindness from retinal detachment·neovascular glaucoma; improved visual prognosis reported with combined anti-VEGF
12. PreventionRegular pediatric eye examinations, an early reporting system for leukocoria, retinal follow-up in muscular dystrophy patients; no known primary prevention
13. References10 references listed with PMID/DOI (below)

1. Historical background

Coats disease was named in 1908 when the Scottish ophthalmologist George Coats described an unusual form of retinal disease in which large amounts of exudate arise from the retinal vessels. Coats originally classified three forms as separate pathologies, but later studies confirmed that they belong to the same pathological spectrum. In 1916, Theodor Leber described 'idiopathic retinal telangiectasia (Leber miliary aneurysms)', which corresponds to a mild form of Coats disease.

In 1956, Algernon Reese unified the Coats and Leber descriptions into a single disease spectrum, establishing the concept of an exudative retinopathy arising from retinal vascular malformation. Subsequently, the introduction of fluorescein angiography (FFA) made it possible to determine the exact location and extent of retinal vascular leakage, and laser photocoagulation became established as first-line treatment. Since the clinical application of anti-vascular endothelial growth factor (anti-VEGF) agents in the 2000s, studies have accumulated showing that combined anti-VEGF and laser treatment improves visual prognosis. In 2024, a large study comprehensively analyzing clinical outcomes of Coats disease in the anti-VEGF era in 656 eyes was published in Ophthalmology Retina.

2. Causes

The direct cause of Coats disease is idiopathic vascular malformation (telangiectasia) of peripheral retinal capillaries and arterioles. In the abnormal vessels, tight junctions between endothelial cells of the blood-retinal barrier are lost, and plasma, lipids, and red blood cells exude into the retina and the subretinal space. The exuded lipids form yellow-white hard exudates and plaque-like lipid deposits around the macula, and with prolonged course progress to exudative retinal detachment.

The cause is mostly idiopathic, with no known systemic cause. The typical feature of unilateral occurrence in boys provides clues to the molecular cause. NDP gene (Norrie disease protein) variants have been reported in some cases, suggesting spectrum overlap with Norrie disease. Retinal vascular changes resembling Coats disease (Coats-like changes) appear in about 60~75% of patients with facioscapulohumeral muscular dystrophy (FSHD), presumably because ectopic expression of the DUX4 gene affects retinal vessels. A somatic mutation hypothesis has also been proposed and is being studied as a mechanism explaining unilateral occurrence and pediatric onset.

3. Genetics

Coats disease is typically a non-hereditary sporadic disease; there is no family history and bilateral occurrence is rare, so it does not follow a classic inheritance pattern.

The diagnostic value of genetic testing is low in typical pediatric Coats disease, but molecular testing may be meaningful in bilateral onset, family history, or associated muscular dystrophy such as FSHD. If the somatic mutation hypothesis is true, high-sensitivity next-generation genomic analysis may be applied to diagnosis in the future.

4. General epidemiology

Coats disease is a rare disease. Accurate prevalence data are limited, but one report estimates about 0.09 per 100,000 population. The sex distribution is overwhelmingly male, with a male:female ratio of about 3:1. Onset is mostly in childhood, with ages 5~10 the most common age range of onset. Adult-onset Coats disease accounts for about 10~20% of all cases and, compared with the pediatric form, often progresses more slowly and is milder.

In a Korean 20-year cohort study of 71 eyes (Scientific Reports 2021), the mean age at diagnosis was about 11 years, about 79% were male, and about 43% already had exudative retinal detachment at diagnosis. Unilateral occurrence without associated systemic disease accounts for about 90%, but bilateral occurrence is rarely reported. It is one of the most common causes of exudative retinal detachment in childhood and, after retinoblastoma, a differential diagnosis for leukocoria.

5. Pathophysiology

The pathophysiology of Coats disease is understood as a cascade of retinal vascular endothelial cell dysfunction and breakdown of the blood-retinal barrier.

Vascular malformation and endothelial abnormalities

Malformative dilation (telangiectasia) of peripheral retinal capillaries and 'pericyte loss' are proposed as the initial lesions. Loss of pericytes reduces vascular support and induces endothelial proliferation, forming saccular dilations (light-bulb aneurysms). Damage to tight junctions between endothelial cells breaks down the blood-retinal barrier.

Exudation and lipid deposition

With breakdown of the blood-retinal barrier, plasma lipoproteins, fibrin, and red blood cells exude into the inner retina and subretinal space. The exudate forms lipid globules that accumulate in a plaque-like fashion beneath the macula and impair macular function. With prolonged course, the lipid deposits form a thick subretinal layer and cause exudative retinal detachment.

Role of VEGF and inflammation

Elevated VEGF concentrations have been confirmed in the aqueous humor and vitreous in Coats disease, and VEGF is understood to contribute to increased vascular permeability and abnormal vessel formation. This is the theoretical basis for anti-VEGF treatment, and its effect as adjunctive therapy is clinically supported.

6. Symptoms

Coats disease is often asymptomatic early on, so diagnosis tends to be delayed.

Early symptoms and how it is discovered

Symptoms in advanced stages

7. Signs

Funduscopic findings

Fluorescein angiography (FFA) findings

Ultrasound findings

B-scan: subretinal exudate with high internal reflectivity; echoes of retinal detachment; no calcification (a point of differentiation from retinoblastoma).

8. Screening

There is no specific population-wide screening program for early detection of Coats disease, but the following tests serve as practical screening.

9. Diagnosis

The core of Coats disease diagnosis is clinical findings + FFA, and differentiation from retinoblastoma is the most important clinical task.

Diagnostic findings

Differential diagnosis (very important)

Staging (Shields classification)

10. Treatment

Laser photocoagulation (first-line treatment)

A treatment that closes abnormal vessels directly with heat. Suppresses vascular leakage and promotes absorption of exudate. Most effective in mild Stage 1~2A. The treatment area is determined on the basis of FFA findings, and repeat treatment is often needed.

Cryotherapy

Applied to far-peripheral lesions that are difficult to reach with laser. Mainly combined with laser. When exudative retinal detachment is present, aimed at treating the vascular lesions beneath the detachment.

Intravitreal anti-VEGF injection (adjunctive treatment)

Bevacizumab, ranibizumab, aflibercept, and others. VEGF inhibition reduces vascular permeability and promotes absorption of exudate. Improved visual prognosis has been reported when combined with laser·cryotherapy (a greater number of anti-VEGF injections associated with a 9.4-letter visual acuity improvement). More effective in combination than when used alone.

Intravitreal steroids

Intravitreal triamcinolone injection aids absorption of exudate. Used in combination with or as an alternative to anti-VEGF.

Surgical treatment

11. Prognosis

The prognosis of Coats disease is determined by the stage at diagnosis and whether the macula is involved. When detected early (Stage 1~2A) and treated with laser or combined anti-VEGF therapy, the likelihood of preserving vision is high. A large 2024 study of 656 eyes confirmed a significant difference in visual improvement in the anti-VEGF combination group compared with laser alone in the anti-VEGF era.

Even after treatment, recurrence·progression occurs in about 30~40%, so long-term follow-up is essential. When submacular lipid deposits are thick, visual recovery may be limited even after the exudate is absorbed. At the total detachment stage of Stage 3B or higher, surgical success rates are low and visual prognosis is poor. With complicating neovascular glaucoma (Stage 4), globe-preserving treatment is very difficult. Compared with the pediatric form, the adult form progresses more slowly and progresses to exudative retinal detachment relatively slowly, so the prognosis is somewhat better. In a Korean cohort study, with a mean follow-up of 4 years after diagnosis, the proportion whose final visual acuity improved or was maintained compared with baseline was about 65%.

12. Prevention

No primary prevention for Coats disease is currently known. As an idiopathic disease, no modifiable risk factors have been identified. Clinically feasible preventive strategies are as follows.

13. References

  1. Coats G. Forms of retinal disease with massive exudation. R Lond Ophthalmol Hosp Rep. 1908;17:440-525.
  2. Shields JA, Shields CL, Honavar SG, Demirci H. Clinical variations and complications of Coats disease in 150 cases. Am J Ophthalmol. 2001;131(5):561-571. PMID: 11336930
  3. Smithen LM, et al. Coats disease diagnosed in adulthood. Ophthalmology. 2005;112(6):1072-1078. PMID: 15882909
  4. Sigler EJ, et al. Coats disease: an overview of classification, management and outcomes. Retina. 2014. PMC: 6552590
  5. Kim J, et al. Clinical features and prognostic factors in 71 eyes over 20 years from patients with Coats' disease in Korea. Sci Rep. 2021;11:6095. PMC: 7969742
  6. Daruich AL, et al. Coats' Disease: A Comprehensive Review of Its Pathophysiology, Diagnosis, and Advances in Treatment. Ophthalmologica. 2025. PMID: 40094375
  7. Blair MP, et al. Clinical Characteristics and Treatment Outcomes in Unilateral Coats Disease. Ophthalmol Retina. 2024. DOI: 10.1016/j.oret.2024.08.016
  8. Villegas VM, et al. The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coats disease. Graefes Arch Clin Exp Ophthalmol. 2017;255:1741-1746. PMID: 28532448
  9. Shields CL, et al. Coats disease as a manifestation of Norrie disease. Retina. 2012;32(1):93-98. PMID: 22080960
  10. Grose E, Brassell A, Hart RD. Coats-like reaction in facioscapulohumeral muscular dystrophy: report of a case and literature review. Can J Ophthalmol. 2021;56(6):e201-e205. PMID: 33932366